We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+5.31%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.63B
AUM Growth
-$447M
Cap. Flow
-$292M
Cap. Flow %
-11.12%
Top 10 Hldgs %
36.37%
Holding
119
New
10
Increased
38
Reduced
30
Closed
12

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$30.1M
2
SRRK icon
Scholar Rock
SRRK
+$23.3M
3
THC icon
Tenet Healthcare
THC
+$19.2M
4
FOLD
Amicus Therapeutics
FOLD
+$14M
5
JANX icon
Janux Therapeutics
JANX
+$10.8M

Top Sells

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$67.2M
2
HUM icon
Humana
HUM
+$46.9M
3
EXAS
Exact Sciences
EXAS
+$43.4M
4
ALGN icon
Align Technology
ALGN
+$29.1M
5
ISRG icon
Intuitive Surgical
ISRG
+$28.1M

Sector Composition

Rank Sector Weight
1 Healthcare 97.8%
2 Consumer Staples 1.85%
3 Financials 0.14%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LUNG icon
76
Pulmonx
LUNG
$97.9M
$5.24M 0.2%
772,151
+80,851
+12% +$532K
NVAX icon
77
Novavax
NVAX
$1.3B
$5.23M 0.2%
650,000
– –
MRSN
78
DELISTED
Mersana Therapeutics
MRSN
$4.91M 0.19%
137,267
+15,396
+13% +$796K
BHVN icon
79
Biohaven
BHVN
$2.19B
$4.85M 0.18%
129,858
+2,300
+2% +$107K
ETNB
80
DELISTED
89bio
ETNB
$4.32M 0.16%
+552,741
New +$4.55M
CYPH
81
Cypherpunk Technologies Inc
CYPH
$72.4M
$3.64M 0.14%
1,266,546
– –
SGMT icon
82
Sagimet Biosciences
SGMT
$591M
$3.55M 0.14%
787,808
– –
FOCL
83
EDAP TMS S.A.
FOCL
$228M
$3.52M 0.13%
1,591,800
+23,800
+2% +$59.7K
MGNX icon
84
MacroGenics
MGNX
$259M
$3.42M 0.13%
1,053,647
– –
ABOS icon
85
Acumen Pharmaceuticals
ABOS
$176M
$3.16M 0.12%
1,838,916
-461,143
-20% -$1.11M
GOSS icon
86
Gossamer Bio
GOSS
$86.1M
$2.96M 0.11%
3,266,960
– –
XLO icon
87
Xilio Therapeutics
XLO
$60.5M
$2.87M 0.11%
214,519
– –
APLS
88
DELISTED
Apellis Pharmaceuticals
APLS
$2.55M 0.1%
80,000
– –
AUTL
89
Autolus Therapeutics
AUTL
$551M
$2.43M 0.09%
1,032,988
– –
NGNE icon
90
Neurogene
NGNE
$729M
$2.18M 0.08%
+95,407
New +$3.55M
ATEC icon
91
Alphatec Holdings
ATEC
$1.47B
$1.84M 0.07%
+200,000
New +$1.6M
APLT
92
DELISTED
Applied Therapeutics
APLT
$1.64M 0.06%
1,917,191
+170,742
+10% +$1.07M
CGEN icon
93
Compugen
CGEN
$221M
$1.51M 0.06%
989,990
– –
CATX icon
94
Perspective Therapeutics
CATX
$342M
$1.42M 0.05%
444,383
+29,987
+7% +$245K
KRRO icon
95
Korro Bio
KRRO
$199M
$1.36M 0.05%
35,719
– –
ADAP
96
DELISTED
Adaptimmune Therapeutics
ADAP
$1.34M 0.05%
2,483,468
+58,000
+2% +$42.3K
ALLK
97
DELISTED
Allakos
ALLK
$1.33M 0.05%
1,100,409
-100,000
-8% -$105K
SPRB
98
Spruce Biosciences
SPRB
$127M
$1.1M 0.04%
34,788
– –
LENZ
99
LENZ Therapeutics
LENZ
$168M
$846K 0.03%
+29,305
New +$893K
VIGL
100
DELISTED
Vigil Neuroscience
VIGL
$802K 0.03%
471,958
– –
1 2 3
4
5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, Rock Springs Capital Management held 119 positions worth $2.63B, down 15% from $3.07B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Rock Springs Capital Management withdrew a net $292M in Q4 2024, closing 12 positions and reducing 30 holdings. Its most notable exit was Humana, an estimated $46.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Consumer Staples and Financials.

Against the trend, Rock Springs Capital Management opened a new position in Scholar Rock worth $31M.

  • Rock Springs Capital Management's largest Q4 2024 buy was Scholar Rock: 716,782 shares worth $31M.
  • Rock Springs Capital Management added most to Blueprint Medicines in Q4 2024, an estimated $30.1M increase.
  • Rock Springs Capital Management's biggest Q4 2024 reduction was UnitedHealth, cutting an estimated $67.2M.
  • Rock Springs Capital Management fully exited Humana in Q4 2024, selling an estimated $46.9M.
  • Rock Springs Capital Management's ten largest holdings make up 36% of its $2.63B portfolio in Q4 2024.
  • Rock Springs Capital Management opened 10 new positions and closed 12 in Q4 2024.
  • Rock Springs Capital Management's portfolio value fell 15% quarter-over-quarter to $2.63B.

Based on Rock Springs Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.